China-based Cure Genetics has raised $17m in series A funding, led by Qiming Venture Partners, with investment from CTS Capital and Ascendin Investment. The company is developing a drug that targets the gene for an inherited form of muscular dystrophy (MD).
China-based Cure Genetics has raised $17m in series A funding, led by Qiming Venture Partners, with investment from CTS Capital and Ascendin Investment. The start-up, which uses gene editing to develop medicines and molecular diagnostics, will use the funds to improve its technology platforms, to fund regulatory filings and clinical trials, and to expand its pipeline.